Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Caribou Biosciences, Inc. (CRBU) stock has tumbled to a 52-week low, reaching a price level of just $0.71. According to InvestingPro data, the stock’s RSI indicates oversold conditions, while maintaining a strong balance sheet with a current ratio of 7.16 and more cash than debt. This latest dip underscores a challenging period for the biotechnology company, which has seen its stock price plummet by an alarming 83.49% over the past year. Investors have been closely monitoring Caribou Biosciences as it navigates through a landscape marked by rapid innovation and intense competition, factors that have significantly impacted its market performance and investor sentiment. The 52-week low serves as a stark indicator of the hurdles the company faces, as it strives to regain its footing in the dynamic biotech sector. With analyst price targets ranging from $3 to $34, InvestingPro analysis suggests the stock may be undervalued at its current market cap of $67 million. Discover 15 additional exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Caribou Biosciences reported a narrower-than-expected loss for the fourth quarter of 2024. The company posted a Q4 loss of $0.39 per share, which was better than analyst estimates of a $0.42 per share loss. However, revenue for the quarter was $2.08 million, slightly below the consensus estimate of $2.12 million and down from $3.6 million in the same quarter last year. Caribou ended 2024 with $249.4 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2026. The company is advancing four clinical programs for hematologic malignancies and autoimmune diseases, with two key clinical data readouts anticipated in the first half of 2025. These include results from the ANTLER Phase 1 trial of CB-010 in large B cell lymphoma and initial data from the CaMMouflage Phase 1 trial of CB-011 in multiple myeloma. For the full year 2024, Caribou reported a net loss of $149.1 million, wider than the $102.1 million loss in 2023, attributed to increased research and development expenses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.